Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Clinical trial NCT05760586 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT05760586
- Sponsor
- Day One Biopharmaceuticals, Inc.
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.